Chonluten
Evidence: D+Immune / Inflammation
Evidence Snapshot
Regulatory Context
Chonluten is not to be represented as an approved respiratory therapy.
Research Takeaway
Chonluten is commonly described as the EDG tripeptide Glu-Asp-Gly.
See all 6 evidence claims →Quick Summary
Chonluten is commonly described as the tripeptide Glu-Asp-Gly (EDG). It has been studied for inflammatory/proliferative signaling in immune-cell models and appears in respiratory-bioregulator literature, but clinical benefit claims remain weakly supported.
Mechanism & Research Overview
In-vitro work reports modulation of inflammatory/proliferative signaling in immune-cell models.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Chonluten is commonly described as the EDG tripeptide Glu-Asp-Gly.
Sources: Peptides regulating proliferative and inflammatory pathways in THP-1 monocyte/macrophage cells
Supported
In-vitro work reports modulation of inflammatory/proliferative signaling in immune-cell models.
Sources: Peptides regulating proliferative and inflammatory pathways in THP-1 monocyte/macrophage cells
Supported
Chonluten appears in respiratory-bioregulator literature, but mechanistic and older clinical descriptions require careful source-level verification.
Sources: Khavinson review discussing respiratory peptide bioregulators
Supported
No robust modern randomized human evidence was identified that establishes benefit for COPD, asthma, chronic bronchitis, or post-infectious lung disease.
Sources: MitoCore Batch 9 human-clinical-evidence literature search audit
Supported
In-vitro anti-inflammatory findings do not establish systemic safety.
Sources: Peptides regulating proliferative and inflammatory pathways in THP-1 monocyte/macrophage cells
Supported
Chonluten is not to be represented as an approved respiratory therapy.
Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
No robust modern randomized human evidence was identified that establishes benefit for COPD, asthma, chronic bronchitis, or post-infectious lung disease.Safety Consideration
In-vitro anti-inflammatory findings do not establish systemic safety.Safety Consideration
A substantial portion of the Chonluten literature comes from overlapping investigators and institutions within the Khavinson/St. Petersburg bioregulator research program. This concentration limits independent replication and generalizability; repeated publications from the same research lineage should not be interpreted as equivalent to independent multicenter replication.
Research Areas Being Studied
Research areas discussed on this page reflect the Immune / Inflammation category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Peptides regulating proliferative and inflammatory pathways in THP-1 monocyte/macrophage cells | 2022 | In-vitro work reports modulation of inflammatory/proliferative signaling in THP-1 monocyte/macrophage cell models, including Chonluten. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check | 2026 | Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Khavinson review discussing respiratory peptide bioregulators | Review discussing respiratory-bioregulator peptides, including Chonluten; mechanistic and older clinical descriptions require careful source-level verification. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-17.
Follow research updates for Chonluten
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.